That hope matters deeply
They all belong to a class of drugs known as glucagon-like peptide-1 receptor agonists (GLP-1RAs), which mimic a hormone (GLP-1) in the body that helps control insulin and blood glucose levels and promotes feelings of satiety
(2024) found that GLP-1 receptor agonists significantly reduced diabetic foot ulcer risk compared to insulin (HR: 0.44, 95% CI: 0.320.60) for short-term use and (HR: 0.74, 95% CI: 0.600.92) for long-term use
[DOI] [PubMed] [Google Scholar] 29.Noguchi T, Katoh H, Nomura S, Okada K, Watanabe M
Combined global sales of GLP-1 RAs exceeded tens of billions in 2025, fueling massive profitability for the developers
Nagashima M, Watanabe T, Terasaki M, et al